Methods for identifying a target site of a cas9 nuclease
US-2015044191-A1 · Feb 12, 2015 · US
CRISPR-related methods and compositions with governing gRNAS
US11390887B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11390887-B2 |
| Application number | US-202016835386-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2020 |
| Priority date | Nov 7, 2013 |
| Publication date | Jul 19, 2022 |
| Grant date | Jul 19, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition comprising: a nucleic acid encoding a first guide RNA (gRNA) molecule; a Cas9 molecule, or a nucleic acid encoding a Cas9 molecule, wherein the Cas9 molecule is an S. aureus or S. pyogenes Cas9 molecule, and a payload comprising an inhibitor of a transcription factor, a post-translational modification enzyme, or a post-transcriptional modification enzyme. 2. The composition of claim 1 , wherein the inhibitor is a siRNA, a shRNA, a ribozyme, an antisense-oligonucleotide, an antibody, or an aptamer. 3. The composition of claim 1 , wherein the inhibitor is a siRNA. 4. The composition of claim 1 , wherein the inhibitor is a shRNA. 5. The composition of claim 1 , wherein the inhibitor is a ribozyme. 6. The composition of claim 1 , wherein the inhibitor is an antisense-oligonucleotide. 7. The composition of claim 1 , wherein the inhibitor is an antibody. 8. The composition of claim 1 , wherein the inhibitor is an aptamer.
Assignees
Inventors
Classifications
Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title
- C12N9/22Primary
Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title
Type of nucleic acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11390887B2 cover?
- Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
- Who is the assignee on this patent?
- Editas Medicine Inc, Broad Inst Inc, The Univ Of Iowa Research Foundation, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12N9/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).